Compare Wockhardt with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs JUBILANT LIFE SCIENCES - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT JUBILANT LIFE SCIENCES WOCKHARDT/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -23.5 14.9 - View Chart
P/BV x 1.2 1.7 71.5% View Chart
Dividend Yield % 0.0 0.9 0.4%  

Financials

 WOCKHARDT   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
WOCKHARDT/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,012898 112.7%   
Low Rs532618 86.1%   
Sales per share (Unadj.) Rs355.9572.0 62.2%  
Earnings per share (Unadj.) Rs-60.336.2 -166.4%  
Cash flow per share (Unadj.) Rs-46.859.5 -78.6%  
Dividends per share (Unadj.) Rs0.014.50 0.2%  
Dividend yield (eoy) %00.6 0.2%  
Book value per share (Unadj.) Rs257.8301.9 85.4%  
Shares outstanding (eoy) m110.63159.28 69.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.3 163.7%   
Avg P/E ratio x-12.820.9 -61.2%  
P/CF ratio (eoy) x-16.512.7 -129.6%  
Price / Book Value ratio x3.02.5 119.3%  
Dividend payout %012.4 -0.1%   
Avg Mkt Cap Rs m85,379120,694 70.7%   
No. of employees `0006.32.4 261.7%   
Total wages/salary Rs m9,37119,260 48.7%   
Avg. sales/employee Rs Th6,295.038,120.6 16.5%   
Avg. wages/employee Rs Th1,498.38,058.4 18.6%   
Avg. net profit/employee Rs Th-1,066.32,414.3 -44.2%   
INCOME DATA
Net Sales Rs m39,36991,108 43.2%  
Other income Rs m1,202357 336.4%   
Total revenues Rs m40,57191,466 44.4%   
Gross profit Rs m1817,390 0.1%  
Depreciation Rs m1,4953,709 40.3%   
Interest Rs m2,5552,198 116.2%   
Profit before tax Rs m-2,83011,840 -23.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582-2,802 127.8%   
Tax Rs m2573,268 7.9%   
Profit after tax Rs m-6,6695,770 -115.6%  
Gross profit margin %019.1 0.2%  
Effective tax rate %-9.127.6 -32.9%   
Net profit margin %-16.96.3 -267.5%  
BALANCE SHEET DATA
Current assets Rs m33,79645,848 73.7%   
Current liabilities Rs m26,91720,897 128.8%   
Net working cap to sales %17.527.4 63.8%  
Current ratio x1.32.2 57.2%  
Inventory Days Days7957 139.7%  
Debtors Days Days8951 175.2%  
Net fixed assets Rs m39,66465,498 60.6%   
Share capital Rs m553159 347.3%   
"Free" reserves Rs m27,96847,930 58.4%   
Net worth Rs m28,52248,089 59.3%   
Long term debt Rs m21,73142,429 51.2%   
Total assets Rs m81,620114,685 71.2%  
Interest coverage x-0.16.4 -1.7%   
Debt to equity ratio x0.80.9 86.4%  
Sales to assets ratio x0.50.8 60.7%   
Return on assets %-5.06.9 -72.5%  
Return on equity %-23.412.0 -194.9%  
Return on capital %-7.712.4 -61.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80712,422 78.9%   
Fx outflow Rs m1,78917,227 10.4%   
Net fx Rs m8,019-4,805 -166.9%   
CASH FLOW
From Operations Rs m68411,215 6.1%  
From Investments Rs m6,302-10,118 -62.3%  
From Financial Activity Rs m-7,6956,574 -117.0%  
Net Cashflow Rs m-6647,612 -8.7%  

Share Holding

Indian Promoters % 74.5 45.6 163.4%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 2.3 8.7 26.4%  
FIIs % 7.7 21.2 36.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 21.1 73.0%  
Shareholders   67,757 23,815 284.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, Developments From the IPO Space, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets fell sharply during closing hours amid fears of rising crude oil prices and weakness in the rupee.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 17, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS